Abstracts tagged "interstitial lung disease"

Abstract Number: 2259 • ACR Convergence 2025
Lung Transplant Outcomes in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis and Meta-analysis
Saud AlHajeri¹, Matthew Major², Darya S. Jalaledin³, Beatrice Daviault⁴, Arusa Shah⁵, Alec Yu⁶, Sabrina Hoa⁷, Robert Levy⁸, Jennifer Wilson¹, Charles Poirier⁴, James Choi⁶, John Yee⁶, Océane Landon-Cardinal⁹, Kun Huang¹⁰ and Hyein Kim¹¹, ¹UBC, Vancouver, BC, Canada, ²University of British Columbia, Vancouver, Canada, ³Université de Montréal, Saint-Lambert, QC, Canada, ⁴University of Montreal, Montreal, QC, Canada, ⁵University of Montreal, Montreal, BC, Canada, ⁶University of British Columbia, Vancouver, BC, Canada, ⁷University of Montreal, Brossard, QC, Canada, ⁸University of British Columbia, Deerfield, IL, ⁹Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ¹⁰University of British Columbia, Vancouver, Surrey, BC, Canada, ¹¹The University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Interstitial lung disease (ILD) is a frequent complication of rheumatoid arthritis (RA), ranging from subclinical ILD to advanced fibrosis, and is associated with significant…
Abstract Number: 2030 • ACR Convergence 2025
Krebs von den Lungen 6 levels (∆KL6) is a reliable marker of disease activity and response to therapy in CTD-ILD
fredeswinda Romero-Bueno¹, lydia Abasolo Alcazar², Mª Jesus Rodriguez-Nieto³, Cristina Vadillo Font⁴, Maria asuncion Nieto⁴, Laura Cebrian⁵, Belen Lopez Muñiz⁶, Jesus Loarce Martos⁷, Juan A Rigual⁷, Hilda Godoy Tundidor⁸, Rosalia Laporta⁹, Irene Llorente Cubas¹⁰, Gema Bonilla¹¹, Luis Gomez Carrera¹², Rosario Garcia Vicuña¹³, Ana Jaureguizar⁷, Jose Luis Morell Hita⁷, Claudia Valenzuela¹⁰ and Olga Sanchez Pernaute¹⁴, ¹University Hospital Fundación Jiménez Díaz"", Madrid, Spain, ²IdISSC. HCSC, Madrid, Madrid, Spain, ³Fundacion Jimenez Diaz (IIS-HUFJD), Madrid, Spain, ⁴Hospital Clínico S Carlos, Madrid, Spain, ⁵Department of Rheumatology, Hospital Universitario Infanta Leonor / Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain, ⁶Hospital Universitario Infanta Leonor, Madrid, Spain, ⁷Hospital Ramón y Cajal, Madrid, Spain, ⁸Hospital Universitario puerta de hierro, Madrid, Spain, ⁹Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ¹⁰Hospital Universitario Princesa, Madrid, Spain, ¹¹Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³Hospital Universitario de la Princesa, Madrid, Spain, ¹⁴Clinica Universidad de Navarra, Madrid, Madrid, Spain
Background/Purpose: Krebs von den Lungen-6 (KL6) is produced by type 2 alveolar epithelial cells. High circulating KL6 levels show a good accuracy in the diagnosis…
Abstract Number: 1751 • ACR Convergence 2025
Disease activity, inflammation, and older age are associated with quantitative interstitial abnormalities in early RA: Results from a multicenter, prospective cohort study
Gregory McDermott¹, Xiaosong Wang², Misti Paudel³, Ying Qi⁴, Emily Kowalski⁵, Grace Qian⁶, Liya Sisay Getachew⁵, Kevin Mueller⁶, Alene Saavedra⁶, Lauren O'Keeffe⁶, Natalie Davis¹, Alison Puri⁷, Kathleen Vanni⁶, Caleb Bolden⁸, Tina Mahajan⁹, Erica Mulcaire-Jones¹⁰, Neda Kortam¹¹, Pierre Antoine Juge¹², Tracy J. Doyle¹³, Marcy Bolster¹⁴, Kevin Deane¹⁵, Dinesh Khanna¹⁰, Bryant England⁹, Raul San Jose Estepar⁶, George Washko⁶ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Brookline, MA, ²Brigham and Women's Hospital, Natick, MA, ³Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ⁴Brigham and Women’s Hospital, Boston, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Boston, ⁷Boston University, Brookline, MA, ⁸Massachusetts General Hospital, Boston, ⁹University of Nebraska Medical Center, Omaha, NE, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹University of Michigan, Ann Arbor, ¹²Hopital Bichat, APHP, Paris, France, ¹³Brigham and Women's Hospital, West Roxbury, MA, ¹⁴Massachusetts General Hospital, Concord, MA, ¹⁵University of Colorado Denver Anschutz Medical Campus, Aurora, CO
Background/Purpose: Quantitative computed tomography (QCT) methods using machine learning have been developed to automatically quantify parenchymal lung features on chest CT imaging. QCT can detect…
Abstract Number: 1564 • ACR Convergence 2025
Validation of a Composite Endpoint for Systemic Sclerosis-Associated Interstitial Lung Disease
Elizabeth Volkmann¹, Holly Wilhalme², Samuel Good², Grace Kim², Jonathan Goldin², Michael Roth² and Donald Tashkin², ¹Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, ²UCLA, Los Angeles
Background/Purpose: The forced vital capacity (FVC) is the most commonly used endpoint in registrational trials for systemic sclerosis-associated interstitial lung disease (SSc-ILD). However, the FVC…
Abstract Number: 1213 • ACR Convergence 2025
Transitional Changes on High Resolution Computed Tomography (HRCT) in idiopathic inflammatory Myopathy- Associated Interstitial Lung Disease (IIM-ILD)
Sangmee Bae¹, Grace Kim², Jihey Lee², Daniela Markovic², Donald Tashkin², Jonathan Goldin², Rohit Aggarwal³ and Christina Charles-Schoeman⁴, ¹UCLA Rheumatology, Los Angeles, CA, ²UCLA, Los Angeles, ³University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA, ⁴UCLA Medical Center, Santa Monica, CA
Background/Purpose: HRCT is used as a surrogate for important histopathological findings when evaluating patients with interstitial lung disease (ILD). Quantitative imaging analysis (QIA) using CT…
Abstract Number: 0963 • ACR Convergence 2025
Increased expression of M2 pro-fibrotic markers in circulating monocytes and cultured monocyte-derived macrophages from systemic sclerosis patients with progressive interstitial lung disease (ILD)
Vanessa Smith¹, Stefano Soldano², Rosanna Campitiello³, Emanuele Gotelli³, Paola Montagna⁴, Tamara Vojinovic⁴, Sabrina Paolino², Carmen Pizzorni², Alberto Sulli² and Maurizio Cutolo⁵, ¹Ghent University Hospital, Gent, Belgium, ²University of Genoa, Genova, Italy, ³University of Genoa, Genoa, Liguria, Italy, ⁴University of Genoa, Genova, ⁵University of Genova, Genova, Italy
Background/Purpose: In the complex pathogenesis of systemic sclerosis (SSc), macrophages are mainly involved in mechanism of progressive tissue fibrosis of skin and internal organs, particularly…
Abstract Number: 0274 • ACR Convergence 2025
Transplant-free survival in patients with systemic autoimmune rheumatic diseases and progressive pulmonary fibrosis in the ILD-PRO Registry
Sonali Bracken¹, Aparna Swaminathan², Jeremy M Weber³, Megan L Neely⁴, Scott Palmer⁴, Erin Wilfong⁵, Ann Chauffe⁶ and Elizabeth Volkmann⁷, ¹Duke University Medical Center, Durham, NC, USA, Apex, NC, ²Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, USA, Durham, NC, ³Duke Clinical Research Institute, Durham, NC, USA, Durham, ⁴Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, USA, Durham, ⁵Vanderbilt University Medical Center, Nashville, TN, USA, Nashville, TN, ⁶Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, Newberry, FL, ⁷Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA
Background/Purpose: Progressive pulmonary fibrosis (PPF) is known to be associated with high mortality, but there are few data on the course of PPF in patients…
Abstract Number: 2258 • ACR Convergence 2025
Clinical Associations of Pulmonary Hypertension in RA Patients with and without Interstitial Lung Disease
Sanjita Gowda¹, Yuri Matusov², Amara Seng¹, Nunzio Bottini³ and Jon Giles⁴, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Cedars-Sinai Medical Center, Los Angeles, ³Cedars Sinai Medical Center, Beverly Hills, CA, ⁴Cedars Sinai Medical Center, Los Angeles, CA
Background/Purpose: Pulmonary diseases are contributors to the morbidity and mortality of RA. Despite the recent surge in studies of RA-associated interstitial lung disease (RA-ILD), there…
Abstract Number: 2017 • ACR Convergence 2025
Baseline and 2-year Follow-up of Pulmonary Function Among CTD-ILD Subtypes
Ivana Ilic, Anchal Sabharwal, Galina Marder and Sonali Narain, Northwell, Great Neck
Background/Purpose: Interstitial lung disease is a major cause of morbidity and mortality in patients with connective tissue disease (CTD-ILD). Evaluation of ILD severity and progression…
Abstract Number: 1750 • ACR Convergence 2025
Urinary Proteomic Signature Identifies Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
Jia Shi¹, Xueting Yuan², Yafang Deng³, Chen Yu⁴, Nan Jiang⁵, Zhengguang Guo⁶, Christian Lood⁷, Mengtao Li⁵, Wei Sun⁶, Qian Wang⁵ and Xinping Tian⁵, ¹University of Washington, Seattle, WA, ²Peking Union Medical College Hospital (CAMS), Beijing, China (People's Republic), ³Peking Union Medical College Hospital. Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Beijing, China (People's Republic), ⁴Peking Union Medical College Hospital, Dong Cheng Qu, Beijing, China (People's Republic), ⁵Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ⁶Peking Union Medical College, Beijing, China (People's Republic), ⁷University of Washington, Division of Rheumatology, Seattle
Background/Purpose: Interstitial lung disease (ILD) is a serious pulmonary complication of rheumatoid arthritis (RA), contributing significantly to morbidity and mortality. Non-invasive tools for identifying ILD…
Abstract Number: 1560 • ACR Convergence 2025
Longitudinal assessment of circulating fibroblast activation protein in systemic sclerosis-associated interstitial lung disease
Bo Broens¹, Conny van der Laken¹, Iris Simons¹, Tamara Dekker¹, Jan Willem Duitman¹ and Alexandre Voskuijl², ¹Amsterdam UMC, Amsterdam, Netherlands, ²Amsterdam University Medical Center, Amsterdam, Netherlands
Background/Purpose: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is difficult to manage due to the heterogeneous disease course. There is a high need for biomarkers to…
Abstract Number: 1202 • ACR Convergence 2025
High Prevalence of Asymptomatic Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: Validation of ACR/CHEST Risk Factors in a Hong Kong Cohort
Ka Ki Yam¹, Lucas Tsz Ho Luk¹, Weng Nga Lao², Chiu Wai Shirley Chan³, Dennis Tin Ho Chan⁴, Billy Tin Lok Lai⁵, Roy Tsz Chung Ho⁶, Vivian Hoi Shan Tang⁷, Ho So⁸ and Iris Tang⁹, ¹Department of Medicine & Geriatrics, Hong Kong, Hong Kong, ²Department of Medicine & Geriatrics, Kwong Wah Hospital, Hong Kong, Hong Kong, ³Division of Rheumatology and Clinial Immunology, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, China, ⁴Department of Medicine, Alice Ho Miu Ling Nethersole Hospital, Hong Kong, Hong Kong, ⁵Department of Medicine, Tseung Kwan O Hospital, Hong Kong, Hong Kong, ⁶Department of Medicine, Queen Elizabeth Hospital, Hong Kong, Hong Kong, ⁷Department of Medicine, North District Hospital, Hong Kong, Hong Kong, ⁸Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong, ⁹Department of Medicine, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Interstitial lung disease (ILD) is a common and severe complication of idiopathic inflammatory myopathies (IIM), adversely impacting clinical outcomes. While the ACR/CHEST guideline recommends…
Abstract Number: 0690 • ACR Convergence 2025
Quantitative 18F-FDG PET-CT of the lungs detects treatment induced changes in patients with early severe diffuse cutaneous systemic sclerosis and interstitial lung disease
Bo Broens¹, esther Nossent¹, Lilian Meijboom¹, Gerben Zwezerijnen¹, julia Spierings², Jeska de Vries-Bouwstra³, Jacob M. van Laar⁴, Conny van der Laken¹ and Alexandre Voskuijl⁵, ¹Amsterdam UMC, Amsterdam, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center, Ultrecht, The Netherlands, Utrecht, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands, ⁴UMC Utrecht, Utrecht, Netherlands, ⁵Amsterdam University Medical Center, Amsterdam, Netherlands
Background/Purpose: Patients with early severe diffuse cutaneous systemic sclerosis (dcSSc) with interstitial lung disease (ILD) have poor prognosis. New tools are needed to improve treatment…
Abstract Number: 0259 • ACR Convergence 2025
Inhaled pirfenidone as an innovative therapeutic approach to treat autoimmune ILD and other forms of Progressive Pulmonary Fibrosis: Phase 2b Study Design
Kristin Highland¹, Colin Reisner², Allison Trucillo³, Deepthi Nair⁴, Felix Woodhead⁴, Howard Lazarus⁴, Craig Conoscenti⁴ and Martin Kolb⁵, ¹Cleveland Clinic, Shaker Heights, OH, ²DevPro Biopharma, Basking Ridge, NJ, ³Avalyn Pharma, Austin, TX, ⁴Avalyn Pharma, Cambridge, MA, ⁵McMaster University, Hamilton, ON, Canada
Background/Purpose: Progressive Pulmonary Fibrosis (PPF) is an increasingly recognized condition, defined in 2022 to address the progression of pulmonary fibrosis in patients with interstitial lung…
Abstract Number: 0308 • ACR Convergence 2024
Interstitial Lung Disease as the First Clinical Manifestation of Connective Tissue Diseases
Juan A. Meraz-Ostiz, Aina Puiggròs-Ferrer, Núria Bou, Irene Carrión-Barberà, Jordi Monfort, Carolina Pérez-García, Diana Badenes, Eva Balcells and Anna Pros-Simon, Hospital del Mar, Barcelona, Spain
Background/Purpose: Interstitial lung disease (ILD) is a common complication of connective tissue diseases (CTDs), significantly influencing prognosis and mortality. The prevalence and characteristics of new…

« Previous Page
1
…
6
7
8
9
10
…
47
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].